Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 278-758-9 | CAS number: 77745-66-5
Endpoint summary
Administrative data
Description of key information
There were no signs of acute toxicity via the oral, dermal or inhalation routes.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 12 600 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Additional information
There are no indications of acute toxicity via the oral route for TiTDP (Lowe 2014). In addition, there was no acute toxicity via the oral, dermal or inhalation routes for close analogue - triisodecyl phosphite (TDP).
Use of TDP dermal acute toxicity data as read-across to TiTDP appears appropriate based on the similar acute toxicity of these alkyl phosphites. From the enhanced read-across justification (Section 13), it is also noted that the corresponding alkyl alcohols (hydrolysis products) for these phosphites also have low dermal toxicity.
Given the extremely low vapour pressure of TiTDP, it is not feasible to test via the inhalation route. Read-across data from TDP for the acute inhalation endpoint has been used in the CSR, though inhalation is not considered to be a major exposure pathway.
Justification for selection of acute toxicity – oral endpoint
No acute oral effects observed at the limit dose.
Justification for selection of acute toxicity – inhalation endpoint
No effects observed in an acute aerosol inhalation toxicty study done on close analog, triisodecyl phosphite. Substance is not volatile and inhalation exposure is not expected to occur so a waiver has been submitted for this endpoint.
Justification for selection of acute toxicity – dermal endpoint
No effects observed in an acute dermal toxicity study done on close analog, triisodecyl phosphite. Substance is classified as a skin sensitiser so exposure to skin is already being controlled. A waiver has been submitted for this endpoint.
Justification for classification or non-classification
The following information is taken into account for any hazard / risk assessment:
There were no signs of acute toxicity via the oral and read-across data from TDP suggests no acute toxicity via the dermal or inhalation routes.
The results justify non classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
